1. Overcoming Barriers to Long-Term Graft Survival
Bruce Kaplan, MD 
American Journal of Kidney Diseases 
Volume 47, Issue 4, Pages S52-S64 (April 2006)
DOI: /j.ajkd
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

2. Fig 1
The impact of acute rejection on half-life (t½). All patients had received primary kidney transplants and had at least 1 year of graft function. (Data from Matas et al.11)
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

3. Fig 2
Pathogenesis of CAN. (Copyright © 2002 Massachusetts Medical Society. All rights reserved. Adapted with permission from Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: N Engl J Med 346: , )
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

4. Fig 3
Renal function after conversion from CsA to TAC therapy in patients at risk for chronic renal allograft failure. To convert SCr in mg/dL to μmol/L, multiply by (Data from Waid.30)
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

5. Fig 4
SCr levels after kidney transplantation: TAC versus CsA. To convert SCr in mg/dL to μmol/L, multiply by (Data from Kaplan et al.31)
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

6. Fig 5
Renal function 2 years after kidney transplantation. Kruskal-Wallis test. To convert SCr in mg/dL to μmol/L, multiply by (Data from Ahsan et al.23)
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

7. Fig 6
Patients with an SCr greater than 1.5 mg/dL at 2 years. Pearson chi-square test. To convert SCr in mg/dL to μmol/L, multiply by (Data from Ahsan et al.23)
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

8. Fig 7
Mean SCr levels in patients treated with CsA in combination with SRL or AZA. All patients also were treated with CsA and prednisone as baseline immunosuppression therapy. To convert SCr in mg/dL to μmol/L, multiply by (Data from Kahan.44)
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

9. Fig 8
Effect of CsA therapy withdrawal on acute rejection rate. Both immunosuppression treatment regimens included SRL and corticosteroids. Abbreviation: NS, not significant. (Data from Johnson et al47 and Oberbauer et al.48)
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

10. Fig 9
Acute rejection after CsA or steroid withdrawal. All patients were treated with a triple-drug immunosuppression regimen of MMF, CsA, and prednisone before either CsA or prednisone therapy was withdrawn. (Data from Smak Gregoor et al.50)
American Journal of Kidney Diseases  , S52-S64DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions